Keros (KROS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$15.0M

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

$15.0M

Gross margin

100.00%

Net income (trailing twelve months)

−$83.2M

Net income (quarter)

−$28.7M

Net income growth (year over year)

+6.47%

Net margin

−553.88%

Return on equity

−17.16%

EPS (trailing twelve months)

−$3.22

Book value per share

$13.23

P/E (trailing twelve months)

—

Price to book

0.84

Debt to assets

8.79%

Payout ratio

—

Dividend yield

—

Company profile

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

• Is Keros (KROS) profitable?

  No. Keros reported a net loss of $83.2M over the trailing twelve months.

• How much revenue does Keros (KROS) make?

  Keros generated $15.0M in revenue over the trailing twelve months.

• How do I buy stock in Keros (KROS)?

  KROS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.